Entera BioENTX 23 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Entera Bio ranks worse than 95.31% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Entera Bio's Free Cash Flow for the
three
months ended in Mar. 2026 was $-3.09 Mil. Entera Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Entera Bio's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Entera Bio's FCF Margin % or its related term are showing as below:
ENTX'
s FCF Margin % Range Over the Past 10 Years
Min: -21797.62 Med: -3768.51 Max: -1590.19
Current: -21797.62
During the past 11 years, the highest FCF Margin % of Entera Bio was -1590.19%. The lowest was -21797.62%. And the median was -3768.51%.
ENTX's FCF Margin % is ranked worse than 95.31% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs ENTX: -21797.62
Entera Bio FCF Margin % Related Terms
Entera Bio FCF Margin % Historical Data
* Premium members only.
The historical data trend for Entera Bio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entera Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Entera Bio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (ENTX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Entera Bio and its competitors. According to the industry distribution chart, Entera Bio ranks #915 out of 960 companies in the Biotechnology industry, placing it in the top 95.3%.
Is Entera Bio's FCF Margin % too high?
Entera Bio's current FCF Margin % is 0.00%. Based on the distribution chart, Entera Bio ranks #915 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's FCF Margin % compare to IMA and MNOV?
According to the Biotechnology industry distribution chart, Entera Bio ranks #915 out of 960 companies for FCF Margin %. This places Entera Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Entera Bio and its competitors. Entera Bio's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Entera Bio (ENTX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score
Get the complete analysis for ENTX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTX has been successfully added to your 
